UroGen Pharma (URGN) Reports In-Line Q1 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. BROS
3. ARM
4. FIS
5. EXPE
6. QCOM
7. CPAY
8. PAYC
9. DDOG
10. EW

Go back to UroGen Pharma (URGN) Reports In-Line Q1 EPS

UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments

May 11, 2023 8:00 AM EDT

Reported JELMYTO® Q1 2023 net product revenues of $17.2 million, an increase of ~27% from Q1 2022 Complete Response data from ENVISION pivotal trial and topline data readout from ATLAS trial on track for summer 2023

PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the first quarter ended March 31, 2023, and provided an overview of recent developments.

2023 is off to a promising start as we reported... More